HealthEquity (NASDAQ:HQY) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

HealthEquity (NASDAQ:HQY - Get Free Report) released its quarterly earnings results on Tuesday. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.16, RTT News reports. The firm had revenue of $330.80 million for the quarter, compared to the consensus estimate of $322.25 million. HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same quarter last year, the business posted $0.80 EPS. HealthEquity updated its FY 2026 guidance to 3.610-3.78 EPS.

HealthEquity Stock Performance

HQY stock traded up $2.31 on Thursday, reaching $115.37. The company's stock had a trading volume of 689,981 shares, compared to its average volume of 819,436. HealthEquity has a 52 week low of $65.01 and a 52 week high of $116.69. The company has a market capitalization of $9.98 billion, a P/E ratio of 105.84, a price-to-earnings-growth ratio of 1.60 and a beta of 0.45. The firm has a fifty day moving average of $90.51 and a two-hundred day moving average of $97.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on HQY shares. The Goldman Sachs Group increased their price objective on HealthEquity from $94.00 to $104.00 and gave the stock a "neutral" rating in a research report on Wednesday. Barrington Research reaffirmed an "outperform" rating and set a $112.00 price objective on shares of HealthEquity in a research report on Friday, April 11th. JMP Securities increased their price objective on HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a research report on Wednesday. Bank of America increased their price objective on HealthEquity from $110.00 to $125.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Wells Fargo & Company increased their price objective on HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $115.82.

Insider Buying and Selling at HealthEquity

In other news, EVP Michael Henry Fiore sold 8,881 shares of the stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the completion of the sale, the executive vice president now owns 56,655 shares in the company, valued at approximately $4,433,820.30. This represents a 13.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert W. Selander sold 5,750 shares of the stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the sale, the director now owns 84,969 shares of the company's stock, valued at $6,597,842.85. The trade was a 6.34% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.